Reuters logo
BRIEF-Novartis says Cosentyx shows long-term efficacy in nail and palmoplantar psoriasis
November 30, 2017 / 6:46 AM / 13 days ago

BRIEF-Novartis says Cosentyx shows long-term efficacy in nail and palmoplantar psoriasis

Nov 30 (Reuters) - Novartis AG:

* NOVARTIS AG - NOVARTIS’ COSENTYX® IS FIRST BIOLOGIC TO SHOW LONG-TERM EFFICACY IN NAIL AND PALMOPLANTAR PSORIASIS, WHICH CAN IMPACT UP TO 90% OF PSORIASIS PATIENTS

here

Further company coverage: (Reporting By Zurich newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below